clinical trial · NCT03775187
Expanded Access to Burosumab
Kyowa Kirin Co., Ltd.·—·available
X-linked HypophosphatemiaTumor-Induced OsteomalaciaBurosumab
brief summary
Individual patient expanded access requests may be considered for patients who have no other treatment options
started
—
primary completion
—
completion
—
last updated
Mar 5, 2025
detailed description
Expanded access may be available outside of the US in countries prior to approval by the local regulatory agencies. For full details, please visit the links provided below.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol